Clinical utility of ramucirumab in non-small-cell lung cancer

Lung cancer is the leading cause of cancer-related mortality worldwide. Non-small-cell lung cancer (NSCLC) accounts for about 85% of all lung cancer cases and approximately 70% of patients with NSCLC have locally advanced or metastatic disease at presentation. In NSCLC patients with advanced or meta...

Descripción completa

Detalles Bibliográficos
Autor principal: Uprety, Dipesh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6659776/
https://www.ncbi.nlm.nih.gov/pubmed/31413541
http://dx.doi.org/10.2147/BTT.S175034

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6659776/
https://www.ncbi.nlm.nih.gov/pubmed/31413541
http://dx.doi.org/10.2147/BTT.S175034

Ejemplares similares